- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07557914
Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
A Multicenter, Prospective, Single-arm Clinical Study Evaluating the Efficacy and Safety of Epalrestat Combined With Hepatic Arterial Chemotherapy Infusion (HAIC), Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable Hepatocellular Carcinoma and Diabetes
The purpose of this study is to evaluate the comprehensive therapeutic efficacy and safety profile of the epalrestat combined with hepatic artery infusion chemotherapy (HAIC), donafenib and tislelizumab quadruple regimen in patients with unresectable hepatocellular carcinoma (HCC) and diabetes.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: Hongbin Zou
- Número de telefone: +8618040026871
- E-mail: hongbinzou300@gmail.com
Locais de estudo
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150085
- Ainda não está recrutando
- Harbin Medical University Cancer Hospital
-
Contato:
- Dongfeng He
- Número de telefone: 18040026871
- E-mail: 2919534184@qq.com
-
-
Jilin
-
Yanji, Jilin, China, 133000
- Recrutamento
- Yanbian University Hospital
-
Contato:
- Songnan Zhang
- Número de telefone: 18040026871
- E-mail: 2919534184@qq.com
-
-
Liaoning
-
Shenyang, Liaoning, China, 110000
- Ativo, não recrutando
- The First Hospital of China Medical University
-
Shenyang, Liaoning, China, 110001
- Ainda não está recrutando
- Liaoning Cancer Hospital
-
Contato:
- Wenheng Zheng
- Número de telefone: 18040026871
- E-mail: 2919534184@qq.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Diabetes mellitus combined with unresectable advanced HCC (BCLC stage C);
- Patients who have the need for treatment, prevention and improvement of diabetic neuropathy;
- Liver function at Child-Pugh grade A or B (≤ 7 points), ECOG PS 0-1;
- Age 18-80 years old. Confirmed as unrectable HCC through pathological or imaging diagnosis;
Exclusion Criteria:
- Severe liver dysfunction: Child-Pugh C grade (≥ 8 points) or active hepatic encephalopathy Illness;
- Extensive extrahepatic metastases (e.g., lung, bone, or peritoneum metastases);
- Severe cardiovascular diseases: Uncontrolled heart failure, recent myocardial infarction;
- Renal failure: Creatinine clearance rate < 30 mL/min;
- Thrombocytopenia (less than 50×10⁹/L) or coagulation dysfunction (INR greater than 1.5);
- Active infection (such as uncontrolled hepatitis B virus replication with HBV-DNA > 2000 IU/mL);
- ECOG PS ≥ 2 or extremely poor overall condition;
- Diabetic patients with acute ketoacidosis or during the period of severe infection;
- Pregnant and lactating women;
- Known history of other malignancy.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Epalrestat plus HAIC, donafenib and tislelizumab
Epalrestat 50mg tid, donafenib 0.2g bid, tislelizumab 200mg per 21days, HAIC (FOLFOX or RALOX) per 21days |
For the first 6 patients in the safety lead-in period, the starting dose of epalrestat was 50 mg, three times per day. If dose-limiting toxicity (DLT) occurred in the first 6 patients, the dose for the second round of 6 patients in the safety lead-in period would be adjusted to 50 mg, twice per day. If DLT occurred in the second round of 6 patients, the dose for the third round of 6 patients in the safety lead-in period would be adjusted to 50 mg, once per day. donafenib 0.2g BID, tislelizumab 200mg/21days Include FOLFOX and RALOX.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
12-month Event-free survival (EFS) Rate
Prazo: From treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs), assessed up to 2 years.
|
The proportion of patients who have remained event-free from the start of treatment until the 12-month time point.(Predefined events include: progression of disease, death for any reason, terminate the treatment due to intolerable AEs.) |
From treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs), assessed up to 2 years.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Event-free survival (EFS)
Prazo: From treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs), assessed up to 2 years.
|
Defined as the time from treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs). |
From treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs), assessed up to 2 years.
|
|
Overall survival (OS)
Prazo: Up to approximately 2 years
|
The OS is defined as the time from the enrollment to death due to any cause. |
Up to approximately 2 years
|
|
Progression free survival(PFS) (Overall)
Prazo: From enrollment to progressive disease (according to mRECIST) or death due to any cause, up to 2 years.
|
The PFS is defined as the time from the enrollment to the first documented progressive disease (according to mRECIST) or death due to any cause, whichever occurs first. |
From enrollment to progressive disease (according to mRECIST) or death due to any cause, up to 2 years.
|
|
Progression free survival(PFS) of intra-hepatic lesions
Prazo: From the enrollment to the first documented progressive disease of intra-hepatic lesions or death due to any cause, up to 2 years.
|
The PFS is defined as the time from the enrollment to the first documented progressive disease of intra-hepatic lesions or death due to any cause, whichever occurs first. |
From the enrollment to the first documented progressive disease of intra-hepatic lesions or death due to any cause, up to 2 years.
|
|
Progression free survival(PFS) of extra-hepatic lesions
Prazo: From the enrollment to the first documented appearance of extra-hepatic lesions or death due to any cause, up to 2 years.
|
The PFS is defined as the time from the enrollment to the first documented appearance of extra-hepatic lesions or death due to any cause, whichever occurs first. |
From the enrollment to the first documented appearance of extra-hepatic lesions or death due to any cause, up to 2 years.
|
|
Objective response rate(ORR) per RESCIST 1.1
Prazo: Up to approximately 2 years
|
The ORR is defined as the proportion of patients with a documented complete response(CR) or partial response(PR) per RECIST 1.1. |
Up to approximately 2 years
|
|
ORR per mRECIST
Prazo: Up to approximately 2 years
|
The ORR is defined as the proportion of patients with a documented CR or PR per mRECIST. |
Up to approximately 2 years
|
|
PVTT response rate per mRECIST
Prazo: Up to approximately 2 years
|
The PVTT response rate is defined as the proportion of patients with a documented CR or PR of PVTT. According to the Vp classification: CR: PVTT disappears or the portal vein becomes completely unobstructed. PR: Decrease in VP classification. SD: Without PR and PD. PD: Increase in VP classification. |
Up to approximately 2 years
|
|
Disease control rate(DCR) per RESCIST 1.1
Prazo: Up to approximately 2 years
|
The DCR is defined as the proportion of patients with a documented complete response(CR), partial response(PR) or stable disease(SD) per RECIST 1.1. |
Up to approximately 2 years
|
|
DCR per mRECIST
Prazo: Up to approximately 2 years
|
The DCR is defined as the proportion of patients with a documented complete response(CR), partial response(PR) or stable disease(SD) per mRECIST. |
Up to approximately 2 years
|
|
Adverse event(AE) per Common Terminology Criteria for Adverse Events(CTCAE) 5.0
Prazo: Up to approximately 2 years
|
The percentage and degree of patients who experience at least one AE, whether or not considered related to the treatment, according to CTCAE version 5.0. |
Up to approximately 2 years
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Haibo Shao, First Hospital of China Medical University
- Investigador principal: Tao Han, First Hospital of China Medical University
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças do Sistema Endócrino
- Neoplasias por local
- Neoplasias
- Doenças Metabólicas
- Neoplasias por Tipo Histológico
- Neoplasias do Aparelho Digestivo
- Doenças do aparelho digestivo
- Distúrbios do Metabolismo da Glicose
- Doenças do Fígado
- Neoplasias Glandulares e Epiteliais
- Adenocarcinoma
- Neoplasias Hepáticas
- Carcinoma
- Doenças Nutricionais e Metabólicas
- Carcinoma Hepatocelular
- Diabetes Mellitus
- tislelizumab
- Donafenib
- Epalrestat
Outros números de identificação do estudo
- kelunshen【2025】2025-861-2
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Consent and privacy: Participants usually only agreed to data use in the original study. Sharing IPD may violate that agreement. And we want to protect our academic credit and avoid misuse of the data.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .